2010-05-27 17:07 by Wolf Kroner

Fighting Crisis in the Chemicals Industry!

Giorgio Squinzi, president of Mapei SpA and Italian Federchimica, describes ways out of recession and outlines futures of the chemicals industry, prospects of construction chemicals in Middle East, and comments on Mapei Group results.

2010-05-13 00:33

Cash in Agbio and Food Markets

Positioning Direvo Industrial in hitherto unfamiliar markets is a major challenge Jörg Riesmeier, new company's COO returned from the US, is facing. How do current value propositions compare to those of competitors? Article Includes in-house comparisons by Direvo of mannanase and phytase competitor products.

2010-05-24 12:49

“We have biosimilars coming …”

June 2010. Jonathan Barnsley, Senior Vice President, Biotech Manufacturing & Process Development Merck Serono, describes opportunities and threats. at issue is process development to ensure peak process performance, selecting alternative technology platforms.

PHARMA INDUSTRY VOICES ON STEM CELL APPLICATIONS

2010-02-10 09:16

Doing our business a little bit differently than the others in industry

January 2010. At issue are other business models than those based on pharmacological treatments, says Dr. Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk in an interview with B2Bioworld on stem cell applications in the pharmaceutical industry with some comments to competitors like Eli Lilly, Pfizer, or Eli Lilly, Sanofi-Aventis.

2010-02-10 09:10

Triggering Regenerative Functions with Transplanted Cells and Small Molecules

February 2010. What requirements stem technologies have to fulfil? What is the relationship to biomarker development? Which types of stem cells are most promising in order to meet Sanofi-Aventis’ strategic development goals? Prof. Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville (FR) describes in the interview with B2Bioworld, how his company approaches stem cells (including iPS cells), the role for small molecule development, and needs for complementary technologies.

2010-02-10 08:36

We are obliged to more and more move away from animal models

January 2010. In an interview with B2Bioworld Prof. Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim and Head of Corporate Board Division Pharma Research Corporate, evaluates prospects for stem technologies and outlines corporate responsibilities, including a comment on BI’s patenting in the field.